Tesamorelin × empower-peptides.com — lab test, lot EMP-TESA-250528-A10, June 2025
Chromate publishes a public verification portal. Any test attributed to this lab can be looked up and confirmed directly with the lab — so this result doesn't rest on our review alone. Click 'Verify' (top right), then enter Job Number + Access Code from the COA
This certificate carries no lookup code.
Test results
This is a purity and identity analysis. Sterility, endotoxins, and heavy metals were not screened — a high purity figure says nothing about those.
About this test
Label 10 mg · Lab measured 9.931 mg
99% of label, basis not stated — shown as printed. Reconstituted with 2 mL, a 50-unit draw holds 2.5 mg using the measured mass, against 2.5 mg on the label — 1% less.
One vial from this lot was weighed by the laboratory, not yours. This page reports what the certificate says; it does not recommend a dose.
Independent HPLC purity analysis of Tesamorelin from empower-peptides.com, performed by Chromate on June 17, 2025. Reported purity: 99.235%. Net content: 9.931 mg against 10 mg labeled (99% of label). Batch EMP-TESA-250528-A10. Sample source: shop-provided. Certificate of analysis attached.
Certificate of analysis
Other lots of Tesamorelin from empower-peptides.com
| Lot | Tested | Lab | Purity | vs label | Status |
|---|---|---|---|---|---|
| TES-E10ZZ03 | 20 Apr 2026 | Bioviridian | 99.8% | 111% | Unverified |
| TES-C10HFK10 | 18 Oct 2025 | freedomdiagnosticstesting.com | 98.211% | 101% | Unverified |
| TES-A205R09 | 28 Sept 2025 | freedomdiagnosticstesting.com | 99.307% | 115% | Unverified |
| TES-SR08-B10 | 28 Sept 2025 | freedomdiagnosticstesting.com | 98.555% | 112% | Unverified |
| EMP-TESA-Z7-250528-A10 | 17 Jun 2025 | Chromate | 99.126% | 106% | Unverified |
Batches this shop has published a certificate for, newest first. A lot whose printed value cannot identify a batch is not listed.
Have you tested this peptide?
Submit your third-party lab test to help the community verify purity claims. Every report is reviewed before publication.
Community discussion